Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:HRMY NASDAQ:LEGN NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$128.57-0.8%$118.06$75.56▼$139.13$6.40B0.52721,602 shs46,458 shsHRMYHarmony Biosciences$26.38-0.9%$32.62$25.95▼$41.61$1.52B0.79701,600 shs115,932 shsLEGNLegend Biotech$33.20-1.6%$34.37$27.34▼$47.79$6.13B0.231.43 million shs284,616 shsPCVXVaxcyte$43.51-1.0%$34.08$27.66▼$118.54$5.65B1.121.79 million shs272,244 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+4.91%+9.16%+10.96%+15.45%+49.92%HRMYHarmony Biosciences-0.78%+0.26%-18.06%-26.90%-24.99%LEGNLegend Biotech+1.47%+4.69%-0.47%-19.96%-24.92%PCVXVaxcyte+2.54%+7.85%+41.74%+17.58%-61.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$128.57-0.8%$118.06$75.56▼$139.13$6.40B0.52721,602 shs46,458 shsHRMYHarmony Biosciences$26.38-0.9%$32.62$25.95▼$41.61$1.52B0.79701,600 shs115,932 shsLEGNLegend Biotech$33.20-1.6%$34.37$27.34▼$47.79$6.13B0.231.43 million shs284,616 shsPCVXVaxcyte$43.51-1.0%$34.08$27.66▼$118.54$5.65B1.121.79 million shs272,244 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+4.91%+9.16%+10.96%+15.45%+49.92%HRMYHarmony Biosciences-0.78%+0.26%-18.06%-26.90%-24.99%LEGNLegend Biotech+1.47%+4.69%-0.47%-19.96%-24.92%PCVXVaxcyte+2.54%+7.85%+41.74%+17.58%-61.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.00Buy$177.9338.40% UpsideHRMYHarmony Biosciences 2.90Moderate Buy$45.5672.69% UpsideLEGNLegend Biotech 2.73Moderate Buy$69.25108.62% UpsidePCVXVaxcyte 2.75Moderate Buy$106.25144.22% UpsideCurrent Analyst Ratings BreakdownLatest HRMY, AXSM, LEGN, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $43.0010/14/2025HRMYHarmony BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/14/2025PCVXVaxcyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/9/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$78.00 ➝ $76.0010/8/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.0010/1/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/30/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/27/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025HRMYHarmony BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$495.03M12.96N/AN/A$1.18 per share108.95HRMYHarmony Biosciences$772.53M1.96$2.90 per share9.11$11.56 per share2.28LEGNLegend Biotech$627.24M9.77N/AN/A$5.70 per share5.82PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A45.59N/A-49.88%-283.22%-33.06%11/3/2025 (Estimated)HRMYHarmony Biosciences$145.49M$3.108.518.480.3323.44%26.34%17.71%11/4/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)PCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)Latest HRMY, AXSM, LEGN, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LEGNLegend Biotech-$0.08N/AN/AN/A$277.91 millionN/A11/4/2025Q3 2025HRMYHarmony Biosciences$0.83N/AN/AN/AN/AN/A11/4/2025Q3 2025PCVXVaxcyte-$1.23N/AN/AN/AN/AN/A11/3/2025Q3 2025AXSMAxsome Therapeutics-$0.80N/AN/AN/A$162.96 millionN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51HRMYHarmony Biosciences0.203.843.80LEGNLegend Biotech0.304.714.57PCVXVaxcyteN/A11.1111.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%HRMYHarmony Biosciences86.23%LEGNLegend Biotech70.89%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%HRMYHarmony Biosciences23.60%LEGNLegend Biotech0.02%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionableHRMY, AXSM, LEGN, and PCVX HeadlinesRecent News About These CompaniesWeiss Ratings Reiterates "Sell (D-)" Rating for Vaxcyte (NASDAQ:PCVX)October 16 at 2:19 AM | americanbankingnews.comVaxcyte, Inc. $PCVX Stock Holdings Increased by Aberdeen Group plcOctober 15 at 3:42 AM | marketbeat.comVaxcyte's (PCVX) Sell (D-) Rating Reiterated at Weiss RatingsOctober 14 at 1:22 PM | marketbeat.comVaxcyte (NASDAQ:PCVX) Shares Up 4.6% - Time to Buy?October 11, 2025 | marketbeat.comBank of America Securities Keeps Their Buy Rating on Vaxcyte (PCVX)October 8, 2025 | theglobeandmail.comVaxcyte Signs 15-Year Agreement with PatheonOctober 8, 2025 | theglobeandmail.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 8, 2025 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 8, 2025 | marketbeat.comBank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)October 8, 2025 | finance.yahoo.com111 Capital Takes Position in Vaxcyte, Inc. $PCVXOctober 6, 2025 | marketbeat.comWhat Does Wall Street Think About Vaxcyte (PCVX)?September 30, 2025 | insidermonkey.comVaxcyte teams up with Thermo Fisher to ensure future vaccine productionSeptember 30, 2025 | msn.comVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in ...September 30, 2025 | finance.yahoo.comVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and ServicesSeptember 30, 2025 | globenewswire.comVaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine StudySeptember 30, 2025 | msn.comBanque Pictet & Cie SA Has $2.71 Million Stock Holdings in Vaxcyte, Inc. $PCVXSeptember 27, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Stake Cut by Assenagon Asset Management S.A.September 27, 2025 | marketbeat.comWe're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn RateSeptember 23, 2025 | finance.yahoo.comStrs Ohio Buys Shares of 16,600 Vaxcyte, Inc. $PCVXSeptember 21, 2025 | marketbeat.comHarbor Capital Advisors Inc. Buys 25,303 Shares of Vaxcyte, Inc. $PCVXSeptember 18, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Vaxcyte (PCVX) with Neutral RecommendationSeptember 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRMY, AXSM, LEGN, and PCVX Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$128.56 -1.02 (-0.78%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Harmony Biosciences NASDAQ:HRMY$26.38 -0.25 (-0.94%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Legend Biotech NASDAQ:LEGN$33.20 -0.53 (-1.56%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Vaxcyte NASDAQ:PCVX$43.50 -0.44 (-0.99%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
